Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label study of migalastat in Fabry disease with amenable GLA variants
2019-000222-21Phase 3Unknown
- Sponsor
- Amicus Therapeutics
- Start
- Jun 2020
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of migalastat in Fabry disease (FD), sponsored by Amicus Therapeutics. Primary endpoint: Safety endpoints. Status: unknown.
02
Drugs
migalastat
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on 2019-000222-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000222-21.